Aethlon Medical, Inc., incorporated on April 17, 1991, is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company's lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer.
The Company operates under two Department of Defense contracts related to a program entitled Dialysis-Like Therapeutics. One is a contract with Defense Advanced Research Projects Agency (DARPA), and the other is a subcontract with Battelle Memorial Institute. Under these contracts, its tasks include the development of a dialysis-like device to prevent sepsis, a fatal bloodstream infection that is often the cause of death in combat-injured soldiers. Specific to the Hemopurifier, the program has focused on validating the capture of viral pathogens and bacterial toxins.
The Aethlon Hemopurifier addresses antiviral drug-resistance in Hepatitis C virus and Human Immunodeficiency Virus-infected individuals and serves as a countermeasure against viral pathogens not addressed by drug or vaccine therapies. In the Company's clinical studies that are conducted in India, safety and efficacy observations of Hemopurifier therapy have been observed in both Hepatitis C virus and Human Immunodeficiency Virus-infected individuals. Delivery of Hemopurifier therapy can occur through the infrastructure of continuous renal replacement therapy and dialysis instruments routinely found in hospitals and clinics. The Hemopurifier is designed to provide a spectrum mechanism to reduce the presence of certain cancer and infectious disease related particles. The Company has conducted Hepatitis C virus treatment studies for Aethlon Hemopurifier.
In addition to treating Hepatitis C virus-infected individuals, the Company has conducted a single proof-of-principle treatment study related to the treatment of Human Immunodeficiency Virus. In the study, Hemopurifier therapy reduced viral load by approximately 90% in a Human Immunodeficiency Virus-Acquired Immunodeficiency Syndrome-infected individual without the administration of antiviral drug therapy.
The Company competes with Asahi Kasei Kurary Medical.
9635 Granite Ridge Dr Ste 100
The company trades on NASDAQ exchange. The company headquarter is located in California, CA. The company was established in the 1991.| Ticker | AEMD |
| Long Name | Aethlon Medical, Inc. |
| Short Name | Aethlon Medical |